keep away from direct sunlight,keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ccc_R08 is an orally available HBV cccDNA inhibitor that reduces extracellular levels of HBV DNA, HBsAg, and HBeAg in a dose-dependent manner. ccc_R08 is investigational for use in the treatment of HBV infections. ccc_R08 has been shown to be effective in the treatment of hepatitis C virus (HCV).
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
1 mg | 在庫あり | ¥ 67,500 |
2 mg | 在庫あり | ¥ 100,000 |
5 mg | 在庫あり | ¥ 166,000 |
10 mg | 在庫あり | ¥ 226,500 |
25 mg | 在庫あり | ¥ 349,000 |
50 mg | 在庫あり | ¥ 454,500 |
説明 | ccc_R08 is an orally available HBV cccDNA inhibitor that reduces extracellular levels of HBV DNA, HBsAg, and HBeAg in a dose-dependent manner. ccc_R08 is investigational for use in the treatment of HBV infections. ccc_R08 has been shown to be effective in the treatment of hepatitis C virus (HCV). |
In vitro | In HepDES19 cells, ccc_R08 (0.3, 1.0, 3.2, 10, 32 µM; 5 days) reduced the levels of cccDNA, protein-free RC-DNA, and double-stranded linear DNA (DL-DNA)[1]. |
In vivo | In the HBV circle mouse model, ccc_R08 (20 mg/kg; oral administration; twice daily for 2 weeks) led to the clearance of cccDNA from the livers of HBV circle mice[1]. |
分子量 | 414.84 |
分子式 | C22H19ClO6 |
CAS No. | 2919019-72-8 |
keep away from direct sunlight,keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 80 mg/mL (192.85 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ccc_R08 2919019-72-8 Microbiology/Virology HBV Inhibitor inhibitor inhibit